Suzhou Curemed Biopharmaceutical Technology Co., Ltd. is located on the 1st and 2nd floors of Building C, 

Tengfei Science and Technology Park, Suzhou Industrial Park. 

It has established a 1,300-square-meter laboratory that meets GMP standards, as well as a 3,000-square-meter GMP production facility and R&D platform. 

It also features a GMP-grade workshop for circular RNA and LNP production, 

and has built a complete upstream circular RNA raw material system (plasmid and protease).

The company specializes in the research and development of next-generation circular mRNA nucleic acid drugs. 

It possesses a proprietary novel cyclization framework, the Clean-PIE system, and proprietary LNP nucleic acid delivery technology. 

Its circular mRNA technology is leading domestically and comparable internationally. 

Currently, the company has applied for over 40 core platform technology invention patents in the field of circular mRNA, as well as multiple PCT international patents. 

Both generations of underlying patents have been granted in the United States and China. 

With a mature production process, the company stands at the forefront globally.

As the only circular RNA company selected for the "Leading the Way" outstanding project of the National Biomedical Innovation Center for nucleic acid drugs,  

Curemed is led by a local technical team consisting of post-80s and post-90s Ph.D. and master's degree holders. 

With over 70 employees, the company boasts comprehensive platforms for research and development, production, and quality control. 

It is committed to building a comprehensive circular mRNA nucleic acid pharmaceutical platform and actively developing high-potential innovative drug pipelines in areas such as infectious diseases, 

tumor immunology, protein replacement, gene therapy, and cell therapy, in order to better meet significant clinical treatment needs.